Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Investigation"
DOI: 10.1080/07357907.2021.1899200
Abstract: Abstract Tumor suppressor genes RB1 and TP53 are altered frequently in prostate cancer (PC), whether RB1 and TP53 inactivation promotes radioresistance remains unclear. Herein, we demonstrated that RB1 loss enhanced ionizing radiation (IR)-induced DNA damage… read more here.
Keywords: radiation; rb1 tp53; prostate cancer; tp53 ... See more keywords
Abstract 1559: Mechanisms responsible for hypersensitivity of small cell lung cancers to novel cyclin A and B RxL macrocyclic peptide inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1559
Abstract: Most cancer-directed targeted therapies are developed using small molecule inhibitors that require a druggable binding pocket on the target of interest. Macrocyclic peptides can selectively block protein-protein interactions required for function and hence can be… read more here.
Keywords: cell; cyclin inhibitors; rb1 tp53; cyclin ... See more keywords
Abstract 6713: RB1 and TP53 restrict lineage plasticity in prostate cancer by regulating chromatin accessibility
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6713
Abstract: Lineage plasticity has been widely recognized in various cancers as a driver of therapeutic resistance, but the molecular basis of this plasticity remains incompletely defined. Evidence from the literature reveals that the inactivation of RB1… read more here.
Keywords: rb1 tp53; lineage plasticity; chromatin accessibility; lineage ... See more keywords